SECTION // 06 — QUERY LOG
BPC-157 TB-500: Frequently Asked Questions, Answered From the Literature
Twenty-five questions about the Wolverine blend — definition, mechanism, evidence, dosing context, safety, and regulatory status — each answered directly and cited where the claim is quantitative.
Definition and overview
What is BPC-157 and TB-500?
BPC-157 is a synthetic 15-amino-acid pentadecapeptide (sequence GEPPPGKPADDAGLV) derived from a human gastric-juice protein; TB-500 is a synthetic N-acetylated heptapeptide (Ac-LKKTETQ) corresponding to the actin-binding region, residues 17-23, of Thymosin Beta-4 [1][3]. The Wolverine blend pairs the two as a tissue-repair stack; it is not a single chemical entity or an approved product.
What is the Wolverine peptide blend?
Wolverine is a research-community name for a two-peptide pairing of BPC-157 and TB-500, marketed and discussed as a tissue-repair stack. It is not a single chemical entity, has no single molecular weight or CAS number, and is not an approved product anywhere [3].
What is the BPC-157 and TB-500 blend used for in research?
Its two components occupy complementary nodes of a tissue-repair network in preclinical work: BPC-157 for cytoprotection, angiogenesis, and tendon/ligament repair in rodent models [1][2], and TB-500 / Thymosin Beta-4 for cell migration, re-epithelialization, and wound healing in animal and biochemical models [3][4]. The assembled blend itself has not been tested in a controlled study [6].
What is the difference between BPC-157 and TB-500?
BPC-157 is a 15-amino-acid pentadecapeptide derived from a gastric-juice protein, acting through VEGFR2-driven angiogenesis and cytoprotection [1][2]. TB-500 is a 7-amino-acid acetylated fragment (Ac-LKKTETQ) of Thymosin Beta-4, acting through G-actin sequestration that regulates cell migration [3]. They differ in size, origin, and primary mechanism, which is why they are paired as complementary repair signals.
Why the two are combined
Why are BPC-157 and TB-500 combined (the Wolverine stack)?
The rationale is complementary mechanisms: BPC-157 supplies a local cytoprotective and pro-angiogenic signal (VEGFR2-Akt-eNOS) [2], while TB-500 / Thymosin Beta-4 supplies an intracellular actin-sequestration signal (1:1 G-actin binding via LKKTETQ) that regulates cell migration [3][4]. The two act through complementary but largely non-overlapping pathways — the basis of the "synergy" claim, which remains a theoretical extrapolation.
How does BPC-157 work compared to TB-500?
BPC-157 works through a cytoprotective and angiogenic route — up-regulating VEGFR2 with downstream Akt-eNOS signaling and modulating the nitric-oxide system [2] — while TB-500 works through actin sequestration that regulates cell migration [3]. They are described as complementary but largely non-overlapping mechanisms, which is the rationale for pairing them in the blend.
How does TB-500 work (actin / Thymosin Beta-4)?
TB-500's LKKTETQ motif binds monomeric G-actin 1:1 and sequesters it, regulating the cytoskeletal dynamics that drive cell migration and re-epithelialization. X-ray crystallography of a gelsolin-domain-Thymosin Beta-4 hybrid bound to actin established this 1:1 dual-end-capping mechanism [3]. Note: most efficacy data attributed to "TB-500" were generated with full-length Thymosin Beta-4, not the 7-mer [4].
Evidence and synergy
Is there any study showing BPC-157 and TB-500 work better together (synergy)?
No. No peer-reviewed study has defined a synergy ratio, dose, or endpoint for the two peptides given together. A 2025 systematic review of BPC-157 in orthopaedic sports medicine (36 studies, only one human, "no clinical safety data") makes no mention of TB-500 or any combination [6]. Synergy is extrapolated from each peptide's separately characterized mechanism, not demonstrated in a controlled combination study.
Is the 'Wolverine' synergy claim actually proven?
No. The synergy of the Wolverine stack is a theoretical extrapolation from two non-overlapping mechanisms, not a finding from a controlled combination study. The most defensible recent review evidence bounds each component honestly and confirms no combination data exist [6][8].
Are there human clinical trials on the BPC-157 + TB-500 combination?
There are no controlled clinical trials of the combination for any indication. Human data exist only for the individual constituents and are themselves thin: BPC-157 has three small pilot studies, and "TB-500" human data are for full-length Thymosin Beta-4 (Phase 1 IV studies), not the heptapeptide [7][8]. The blend's human efficacy and combination safety are unproven.
What is the latest research on BPC-157 and TB-500?
The freshest defensible literature is review-level: a 2025 systematic review and a 2025 narrative review of BPC-157, both concluding the evidence is low-tier and that BPC-157 should be treated as investigational [6][8], and a 2026 Sports Medicine narrative review of approved and unapproved musculoskeletal peptides listing both BPC-157 and TB-500, noting animal-model promise but scarce human safety data and no regulatory approval [7].
What do doctors and reviews say about the BPC-157 + TB-500 blend?
Recent peer-reviewed reviews are cautious: they describe preclinical promise for the constituents but emphasize that human data are extremely limited, that BPC-157 should be considered investigational given regulatory controversy and non-regulated availability, and that rigorous human safety data for unapproved musculoskeletal peptides are scarce with potential for serious harm [6][7][8].
Efficacy by tissue
Does the BPC-157 TB-500 blend help tendon and ligament injuries?
The tendon/ligament evidence is preclinical and single-compound. BPC-157 accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional, and microscopic measures [1], and Thymosin Beta-4 (TB-500's parent) has been studied in animal ligament-injury models [4]. No controlled study has tested the combined blend in tendon or ligament injury [6].
Does BPC-157 and TB-500 help muscle tears and recovery?
Muscle-repair signals are preclinical and single-compound: BPC-157 has been studied in rat muscle crush and myotendinous-junction injury, and Thymosin Beta-4 acts as a chemoattractant for myoblasts [4]. A counter-result: in mdx mice, chronic Thymosin Beta-4 increased regenerating fibers but did not improve strength or cardiac function [4]. No combination muscle-recovery trial exists.
Do BPC-157 and TB-500 promote angiogenesis (new blood vessels)?
Both promote angiogenesis by distinct routes in preclinical models. BPC-157 up-regulates VEGFR2 and promotes its internalization with downstream VEGFR2-Akt-eNOS signaling, increasing vessel density and blood-flow recovery in ischemic muscle [2]. Thymosin Beta-4 (TB-500's parent) promotes endothelial migration and angiogenesis, including in aged animals with otherwise poor wound healing [4].
Dosing context
How do you cycle BPC-157 and TB-500?
No validated human cycling protocol exists. Community "loading then maintenance" blend protocols have no controlled-trial basis, and a rat embolic-stroke study found Thymosin Beta-4 dosing non-monotonic (18 mg/kg gave no benefit), undermining "more is better" loading rationales [4]. Component animal studies use widely differing schedules by species and route [9].
What is the half-life of BPC-157 and TB-500?
No validated human pharmacokinetic half-life exists for either constituent at research-use doses, and none for the blend. BPC-157's elimination half-life was reported as under 30 minutes in a rat/dog PK study [9]. Human IV full-length Thymosin Beta-4 showed dose-proportional PK, but no specific half-life is established for the TB-500 heptapeptide [9].
How do you reconstitute a BPC-157 / TB-500 blend (10mg)?
Both constituents are supplied as lyophilized powders for research use, reconstituted in bacteriostatic or sterile water and refrigerated [9]. Commercial vials are commonly labeled with a combined per-vial mass (for example, 10 mg plus 10 mg), but product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed [3]. No human-use reconstitution instructions apply to a research chemical.
How often should you inject BPC-157 and TB-500?
There is no validated human injection frequency for the blend. The underlying animal studies use widely differing schedules — for example, Thymosin Beta-4 at 150 microg twice weekly for six months in one mouse study [4] — and community frequency protocols have no controlled-trial basis. The defensible framing describes doses "studied at X in [species]," not recommended human schedules [9].
Safety and regulatory
What are the side effects of BPC-157 and TB-500?
The assembled blend has no controlled human safety data. Component human data are limited: a Phase 1 study of full-length Thymosin Beta-4 was well tolerated, but a 2026 review cautions that rigorous human safety data for unapproved musculoskeletal peptides are scarce, with potential for serious harm [7]. The principal theoretical concern is the pro-angiogenic, pro-migratory tumor signal associated with Thymosin Beta-4 [4].
Does TB-500 cause cancer or promote tumor growth?
Thymosin Beta-4 has been implicated in tumor metastasis and angiogenesis — the same pro-migratory, pro-angiogenic properties that aid repair could theoretically support tumor progression, a concern that compounds when two pro-repair peptides are combined [4]. This is a recognized safety signal, not a demonstrated effect of the blend; no carcinogenicity data exist for the combination.
Are BPC-157 and TB-500 FDA approved or banned by WADA?
Neither is approved by the FDA for human use, and the blend has no approved therapeutic indication. In 2023, FDA placed BPC-157 in Category 2 — a category of bulk drug substances not eligible for routine 503A pharmacy compounding pending further evaluation — and the thymosin beta-4 fragment (LKKTETQ) known as TB-500 was placed in Category 2 in the same update [10]. Both constituents are prohibited by WADA: BPC-157 under S0; TB-500 / thymosin beta-4 under prohibited peptide and growth-factor categories [9].
Is Wolverine legal?
Wolverine is not an approved product, and its two components are FDA Category 2 bulk substances currently restricted for 503A pharmacy compounding [10]. Both are prohibited in sport by WADA [9]. Both components are on the agenda of a July 23-24, 2026 FDA PCAC meeting as candidates for the 503A bulks list — a scheduled review, not a change in current status [13]. See Wolverine legal status and FDA 503A category for the full account.
Can you get BPC-157 from a compounding pharmacy?
As of today, BPC-157 is an FDA Category 2 bulk drug substance and is not within FDA's enforcement-discretion policy for routine 503A compounding while that status stands [10][11]. Legally compounded access generally requires a licensed-prescriber evaluation and a valid, patient-specific prescription filled by a 503A pharmacy or 503B facility — but only for ingredients eligible under the bulk-substance rules [11]. BPC-157 is on the July 2026 PCAC agenda for evaluation [13].
What is the FDA 503A status of Wolverine?
Wolverine has no status of its own — it is a two-peptide blend, not a single substance — but both of its components are FDA Category 2 for 503A compounding, effective with the September 29, 2023 update to the nominated-substances list, on safety-risk grounds [10][11]. Both BPC-157 and TB-500 appear on the July 23-24, 2026 PCAC agenda as substances being considered for inclusion on the 503A bulks list — a scheduled evaluation, not a listing decision [13].